Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.
Also called NCT01196819
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 458 participants
- Registry
-
NCT01196819
-
- Other papers using this trial's data
- A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial
- [Long term safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of coronary de novo lesions]
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01196819. Randomized; double masking; primary purpose treatment. Start 2010-09 (actual); primary completion 2012-05 (actual). Results posted on 2018-02-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Firehawk
- Intervention (Device)
- Xience V
- Lead sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Record details
- Record id
cardio:ct-nct01196819- Content hash
491df589ccdd5353e46e6ba7a81b9d1c83bd9075174dbe6e51ab0636a38562a5